Business
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and
About this update from Spruce Biosciences, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nSpruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfillipo syndrome type B (MPS IIIB) will be presented at the 22nd Annual WORLDSymposium™ taking place February 2-6, 2026 in San Diego. A second presentation will detail divergent outcomes in two male siblings, one of whom was treated with TA-ERT in a clinical trial while the other received care without treatment.\n\n\nWORLDSymposium 2026 Presentation Details\n\n\nTitle: Long-term administration of tralesinidase alfa enzyme replacement therapy (TA-ERT) results in profound and durable reduction of heparan sulfate (HS) and stabilization of cognitive function and cortical gray matter volume (CGMV) in patients with Sanfilippo syndrome type B (MPS IIIB)\nPlatform Presentation Date & Time: 1:42 – 1:54 p.m. PT on February 5, 2026\nLocation: Harbor Ballroom\nPresenter: Nicole Muschol, M.D., International Center for Lysosomal Disorders (ICLD) at the University Medical Center Hamburg-Eppendorf in Germany\nAuthors: Nicole Muschol, M.D.; Mona Lindschau, M.D.; Ilyas Okur, M.D.; Fatih Ezgu, M.D.; Maria J. de Castro Lopez, M.D.; Spyros Batzios, M.D.; Igor Nestrasil, M.D.; Saba Sile, M.D.; Ting Chang, Ph.D.; Jeffrey Zhang, Ph.D.; Javier Szwarcberg, M.D., M.P.H.; Paul Harmatz, M.D.\n\n\nThese data will also be presented as poster #259 on February 5 from 3:30 – 5:30 p.m. PT at Kiosk 30-B\n\n\nTitle: Divergent neurocognitive outcomes in mucopolysaccharidosis (MPS) type IIIB siblings: Tralesinidase alfa versus supportive management (poster #64)\nPoster Presentation Date & Time: 3:30 – 5:30 p.m. PT on February 5, 2026\nLocation: Kiosk 8-C\nPresenter: Irene J. Chang, M.D., Assistant Professor at the University of California, San Francisco\nAuthors: Irene J. Chang, M.D.; Jacqueline Madden, P.N.P.; Erin Jozwiak, N.P.; Saba Sile, M.D.; Ting Chang, Ph.D.; Javier Szwarcberg, M.D., M.P.H.; Paul Harmatz, M.D.\n\n\nAbout Spruce Biosciences\n\n\nSpruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neur...